complement system
Novo throws weight behind budding rare disease pipeline
Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments
Actionable Insights Powered by AI
Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments